Zyvox -- Drug Prescription With Hidden Revelation
Reference To Karl Loren Article
Top

The drug described on this page was prescribed for Jean on the
day she left the hospital. There was no special warning or explanation
about this drug -- it was "just" one of three different antibiotics the hospital
gave us -- to get the prescriptions filled at our own expense at our local
pharmacy. Generally the stay at the hospital included her major surgery to
remove her esophagus and the biopsy findings of no cancer! That was the
good news. There was, however, some very poorly practiced medicine at that
same hospital -- not by our doctor, but nonetheless it certainly seems to rise
to the standard of "medical malpractice" that could have resulted in Jean's
death. This is the page that describes that situation.
[Note: I sent a FAX to the
surgeon about my concerns for the cost of this drug, and its use, and even
though it was a Saturday, she was in her office, called us, and when she
realized the cost, she said that we should just skip this drug. She
rather indicated that it was just an "extra" source of antibiotic help."
She certainly did not describe some specific type of bacteria which was
resistant to all other forms of antibiotic, and therefore justify the use of
this one. It is also certainly true that she had prescribed two OTHER
antibiotics which are rather common.]
The manufacturer of this drug, however, says the following:
To reduce the development of
drug-resistant bacteria and maintain the effectiveness of ZYVOX and other
antibacterial drugs, ZYVOX should be used only to treat or prevent
infections that are proven or strongly suspected to be caused by susceptible
bacteria. When culture and susceptibility information are available, they
should be considered in selecting or modifying antibacterial therapy. In the
absence of such data, local epidemiology and susceptibility patterns may
contribute to the empiric selection of therapy. (Source)
When I found that ONE of these three antibiotics cost $1,500 for
the amount prescribed, and that it could only be obtained by special order --
three day delay for receipt -- I went looking, doing my usual research.
What I found disturbed me and I have recounted these findings on THIS page.
This drug was prescribed for Jean as she left the hospital after her surgery
for removal of the esophagus. When I went to obtain the drug, by the
prescription I had received at the hospital, I found that the dosage I was
supposed to get cost $1,500, and could not be obtained except by special order
(three days). So, I decided to do more research on it.
When I got the prescription at the hospital, the nurse also gave me a printed
information sheet from a source called "Micromedex Healthcare Service" which
described this drug which said, simply, "Treats bacterial
infections. This medicine is an antibiotic."
I found many references to this drug on the web, including so-called "cheap"
versions at about $1,200 for the same quantity that my local drug store would
have charged $1,500.
I found many references to the various uses for this drug. They seemed
rather straightforward to me -- the drug was used for special types of infection
where the infection had proven to be resistant to the normal antibiotics.
Return To Top
Then I looked at the information provided about this drug by the FDA, and
found the information published below -- this is the official FDA information
about this drug. Click here to jump to that reference on this
page.
The FDA information included some startling data that I found no where else
-- and made me wonder about an apparent deliberate effort to hide this
information.
In
other words, the FDA information, prominent in mention, suggests that this is a
drug used to treat "hospital-acquired infections."
"What does this mean," I asked myself. "Could
Jean have acquired some infection IN THE HOSPITAL that is so resistant to other
antibiotics that only this very expensive drug would work?"
And, said I to myself, "Is the hospital giving me an
'information sheet' about this drug which deliberately omits this stunning
information?" And, further, "Are all the
dozens of pages on the web ALSO omitting this stunning information that,
perhaps, the drug is needed particularly to treat 'infections
acquired in a hospital'?"
And, I couldn't help thinking that, "The number four
cause of death in the United States is drugs improperly given in hospitals!!!"
Click here for that
full story.
|
The authors
analyzed 39 studies of hospital patients from 1966 to 1996. Serious
drug reactions affected 6.7% of patients overall and fatal drug
reactions 0.32%, the authors reported in Wednesday's Journal of the
American Medical Association.
In the study, serious injury was
defined as being hospitalized, having to extend a hospital stay or
suffering permanent disability.
The most surprising
result was the large number of deaths, the authors said. They found
adverse drug reactions ranked between fourth and sixth among leading
causes of death, depending on whether they used their most
conservative or most liberal estimate. (Source) |
and
|
JAMA. 1998;279:1200 and 1216
COMMENT: There is
NO QUESTION that this is the biggest medical story this
week. Even I am shocked on this one. It is hard to believe
that JAMA actually published this information. If you go
into the hospital, there is a one in 15 chance that you will
have an adverse reaction to a drug. Those are quite high
numbers. Even more startling is that there is a one in 312
chance that the adverse reaction will result in death. This
is such a high number that it is the FIFTH leading cause of
death in this country. It is important to remember that this
analysis was only done for hospitalized patients. The number
is clearly higher as many more prescriptions are written for
patients outside of the hospital. No, this does not mean one
should never enter the hospital or never use drugs. I am
very grateful that those resources exist and there are
clearly times when they are necessary. However, it is
important to try every last natural therapy before you
resort to drugs or hospitalization.
(net
source) |
|
Was I on to something?
I think so!
Was there an "error" at the hospital which caused Jean to get an infection
which was so resistant to other antibiotics that this very new, and extremely
expensive antibiotic might be required?
Return To Top
You be the judge. Here is what happened.
Jean had a swallowing test,
described here,
in July 2004. There was no question of "posture" for this test -- Jean stood
upright for the test.
However, after the surgery the surgeon told Jean that she should
not, ever again, eat or drink while lying in bed, or in a prone posture.
In fact, she told Jean that Jean should always eat while sitting up, straight,
in a chair. Then, further, Jean should not go to bed, or lie flat, for
about an hour.
Nonetheless, when we went to the room for the swallowing test
the technician there asked Jean to get on the table for the X-Ray. We
could see two different types of X-Ray arrangements -- one was next to a "chair"
that someone could sit in during the test. The "table" was apparently only
for getting tested while the body was flat, or slightly inclined.
When the doctor arrived to do the actual test, Jean protested
that she had been told by her surgeon to never swallow anything while lying
flat. I'm not sure what the doctor said, but he basically ignored this
data and insisted that Jean continue to lie flat on the table.
Jean did. She won't do this again.
So, Jean did the swallowing test while lying flat, and the
doctor mentioned that she "aspirated" == which means that some of the liquid
went down into her lungs -- that causes pneumonia, and could cause death.
The surgeon did not criticize that doctor, but has rescheduled
another swallow test (the right away).
Source
FDA TALK PAPER
Food and Drug Administration
U.S. Department of Health and Human Services
Public Health Service 5600 Fishers Lane Rockville, MD 20857
Return To Top
FDA Talk Papers are prepared by the Press Office to guide FDA
personnel in responding with consistency and accuracy to questions
from the public on subjects of current interest. Talk Papers are
subject to change as more information becomes available.
FDA APPROVES ZYVOX, THE FIRST ANTIMICROBIAL DRUG IN A NEW CLASS
FDA today approved Zyvox (linezolid),
the first antibacterial drug in a new class to treat infections
associated with vancomycin-resistant Enterococcus faecium (VREF),
including cases with bloodstream infection. Zyvox also received
approval for treatment of hospital-acquired pneumonia and
complicated skin and skin structure infections, including cases due
to methicillin-resistant Staphylococcus aureus (MRSA). In addition,
approval was granted for treatment of community-acquired pneumonia
and uncomplicated skin and skin structure infections. The following
may be used to respond to questions.
Return To Top
Infections due to Enterococcus faecium and MRSA are a particular
problem in hospitalized or immunocompromised individuals. These
organisms are often resistant to multiple antibiotics. Vancomycin
has, for many years, served as the treatment of last resort for
these infections. In 1989, the first case of vancomycin-resistant
Enterococcus faecium (VREF) was reported in this country. Since
then, there has been a rapid increase in the incidence of VREF
infections, as well as a dramatic increase in the incidence of MRSA
infections. There have been limited therapeutic options available
for patients with these infections.
Zyvox is the first in a new class of synthetic drugs -- the
oxazolidinone class -- approved for use in the United States and the
world. It is also the first drug in over 40 years to be introduced
into the US market for treatment of MRSA infections.
Zyvox's approval was supported by controlled clinical trials that
enrolled more than 4000 patients. The approval for VREF infections
was based on a dose-comparison study in which 145 patients were
treated with Zyvox (600 mg or 200 mg) every 12 hours for VREF
infection. Types of VREF infections studied included complicated
intra-abdominal infections, complicated skin and skin structure
infections, urinary tract infections, and bacteremia of unknown
origin. The cure rate for Zyvox was 67 percent in the high-dose arm
and 52 percent in the low-dose arm.
Return To Top
Zyvox was also found to be as effective as vancomycin for
treatment of hospital-acquired pneumonia, including cases due to
MRSA, in a controlled clinical trial involving about 400 patients.
The approval for complicated skin and soft tissue infections,
including those caused by MRSA, was based on a controlled clinical
trial of approximately 800 patients comparing linezolid with
oxacillin/dicloxacillin. Additional information on the use of
linezolid in the treatment of cases of hospital-acquired pneumonia
and skin and skin structure infection caused by MRSA came from a
supportive study comparing linezolid to vancomycin.
The most frequently reported side effects attributed to Zyvox in
the clinical studies were headache, nausea, diarrhea, and vomiting.
The most important laboratory test change was a decrease in platelet
counts.
Zyvox may interact with certain other drugs, including
over-the-counter cold remedies that contain pseudoephedrine or
phenylpropanolamine, and cause an increase in blood pressure.
Patients receiving Zyvox should inform their physicians if they are
taking such medications.
Pharmacia and Upjohn, the drug's manufacturer, anticipates that
therapy with Zyvox will be initiated principally in the hospital or
institutional care setting. Due to concerns about inappropriate use
of antibiotics leading to an increase in resistant organisms,
prescribers should carefully consider alternatives before initiating
treatment with Zyvox in the outpatient setting.
Return To Top
FDA's approval follows the recommendations of the Anti-Infective
Drugs Advisory Committee. Their recommendation for approval of these
indications was based on the results of clinical studies presented
at a meeting of the Committee on March 24, 2000.
Pharmacia and Upjohn, based in Kalamazoo, Mich., developed Zyvox
and will market it in the United States.
####
FDA News Page
| FDA Home Page
Return To Top
Office of Public Affairs
Hypertext uploaded by
clb
2000-APR-18.
|
This
web site is a breath
of fresh air in a world of pollution.
|